文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者就诊特征与抗VEGF治疗启动的差异:基于美国眼科学会IRIS注册中心的分析

Disparities in Presentation and Anti-VEGF Therapy Initiation for Neovascular Age-Related Macular Degeneration: An Analysis of the Academy IRIS® Registry (Intelligent Research in Sight).
PubMed 文献 · Ophthalmology · 2025-07-28

该回顾性队列研究纳入2016年10月至2021年10月美国眼科学会IRIS注册中心新诊断的新生血管性年龄相关性黄斑变性患者918759例,评估人口学特征和就诊视力与抗VEGF治疗启动的关系。78.3%的患者在1年内启动治疗,黑人、亚裔、西班牙裔、年龄小于60岁及低视力状态与较低的启动率相关。作者认为改善治疗 uptake 的努力可优先关注启动率较低的群体。

要点

  • 918759例新生血管性年龄相关性黄斑变性患者中,78.3%在1年内启动抗VEGF治疗,71.1%在1个月内接受首次注射。
  • 黑人(RR 0.91)和亚裔(RR 0.95)患者较白人更不易启动治疗,西班牙裔较非西班牙裔低4%(RR 0.96)。
  • 视力差于20/40至20/200者较20/20或更好者更易启动治疗(RR 1.14),而手动视力(RR 0.72)和光感或更差视力(RR 0.49)者更不易启动。

核心结论

  • 超过20%的新生血管性年龄相关性黄斑变性患者在就诊后1年内未启动治疗。
  • 结果提示,黑人、亚裔、西班牙裔、年龄小于60岁及低视力状态与较低的治疗启动率相关。
  • 作者认为,改善治疗 uptake 的努力可优先关注启动率较低的群体。

研究设计与样本

  • 回顾性队列研究,纳入2016年10月至2021年10月美国眼科学会IRIS注册中心新诊断的新生血管性年龄相关性黄斑变性患者。
  • 采用多变量泊松回归模型评估人口学特征、就诊视力与抗VEGF治疗启动之间的关联。
  • 主要结局指标为首次就诊后12个月内启动至少1次抗VEGF注射。

主要发现

  • 共纳入918759例患者(61.5%女性,82.3%白人),男性、黑人和西班牙裔患者诊断新生血管性年龄相关性黄斑变性的年龄更轻(P < 0.001)。
  • 719204例患者(78.3%)在1年内启动抗VEGF治疗,其中653340/918759例(71.1%)在1个月内接受首次注射。
  • 多变量回归中,黑人患者(RR 0.91;95%CI 0.89-0.93;P < 0.001)和亚裔患者(RR 0.95;95%CI 0.93-0.97;P < 0.001)较白人患者更不易启动治疗。
  • 西班牙裔患者较非西班牙裔患者启动治疗的可能性低4%(RR 0.96;95%CI 0.95-0.98;P < 0.001)。
  • 60岁以上患者较50-59岁患者更易启动治疗(所有年龄组比较P < 0.001),西部地区患者较南部地区更易启动治疗(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate disparities in presentation and initiation of anti-VEGF therapy among patients with neovascular age-related macular degeneration (nAMD). DESIGN: Retrospective cohort study. PARTICIPANTS: Patients with nAMD newly diagnosed between October 2016 and October 2021 from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). METHODS: Associations between demographic characteristics, presenting visual acuity (VA), and the initiation of anti-VEGF treatment were assessed using multivariable Poisson regression models. MAIN OUTCOME MEASURES: Treatment initiation with ≥ 1 anti-VEGF injections within 12 months after first presentation with nAMD. RESULTS: Among the 918 759 patients with nAMD (61.5% female, 82.3% White), male, Black, and Hispanic patients demonstrated nAMD at younger ages (P < 0.001). Of these, 719 204 patients (78.3%) initiated anti-VEGF treatment within 1 year, with 71.1% of patients (653 340/918 759) receiving the first injection within 1 month. In multivariable regression analysis, Black patients (rate ratio [RR], 0.91; 95% confidence interval [CI], 0.89-0.93; P < 0.001) and Asian patients (RR, 0.95; CI, 0.93-0.97; P < 0.001) were less likely to initiate treatment compared with White patients. Hispanic patients were 4% less likely to initiate treatment than non-Hispanic patients (RR, 0.96; 95% CI, 0.95-0.98; P < 0.001). Patients older than 60 years (vs. those 50-59 years of age) were more likely to initiate treatment (P < 0.001 for all age group comparisons), as were patients from the West (vs. South) region (P < 0.001). Among 701 309 patients with VA data, patients with VA of worse than 20/40 to 20/200 were more likely to initiate treatment (RR, 1.14; 95% CI, 1.12-1.15) than those with 20/20 or better VA, whereas those with hand movements VA (RR, 0.72; 95% CI, 0.69-0.75) and light perception or worse VA (RR, 0.49; 95% CI, 0.44-0.54; all P < 0.001) were less likely to initiate treatment. CONCLUSIONS: Over 20% of patients with nAMD did not initiate treatment within 1 year of presentation. Results suggest that lower treatment initiation rates are associated with Black and Asian race, Hispanic ethnicity, age younger than 60 years, and low-vision status. Efforts to improve treatment uptake might prioritize groups with lower initiation rates. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Acharya B, Momenaei B, Zhang Q, et al. Disparities in Presentation and Anti-VEGF Therapy Initiation for Neovascular Age-Related Macular Degeneration: An Analysis of the Academy IRIS® Registry (Intelligent Research in Sight). Ophthalmology. 2025. PMID: 40738331. doi:10.1016/j.ophtha.2025.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。